CAD 1.62
(-7.43%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 7.21 Million CAD | -41.59% |
2022 | 12.34 Million CAD | -28.58% |
2021 | 17.28 Million CAD | 654.56% |
2020 | 2.29 Million CAD | 110.52% |
2019 | 1.08 Million CAD | -14.01% |
2018 | 1.26 Million CAD | 157.9% |
2017 | 490.6 Thousand CAD | 73.69% |
2016 | 282.46 Thousand CAD | 0.0% |
2014 | 180.08 Thousand CAD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 6.05 Million USD | 10.66% |
2024 Q2 | 4.79 Million USD | -20.68% |
2023 Q4 | 5.46 Million USD | -17.65% |
2023 FY | 7.21 Million CAD | -41.59% |
2023 Q1 | 9.65 Million USD | -42.35% |
2023 Q2 | 7.8 Million USD | -19.23% |
2023 Q3 | 6.64 Million USD | -14.88% |
2022 Q1 | 18.44 Million CAD | -16.31% |
2022 Q4 | 16.75 Million CAD | 11.98% |
2022 FY | 12.34 Million CAD | -28.58% |
2022 Q3 | 14.96 Million CAD | -6.76% |
2022 Q2 | 16.04 Million CAD | -12.99% |
2021 Q4 | 22.03 Million CAD | 181.33% |
2021 Q3 | 7.83 Million CAD | 6.81% |
2021 Q2 | 7.33 Million CAD | -11.09% |
2021 FY | 17.28 Million CAD | 654.56% |
2021 Q1 | 8.24 Million CAD | 260.09% |
2020 FY | 2.29 Million CAD | 110.52% |
2020 Q2 | 2.87 Million CAD | -14.39% |
2020 Q1 | 3.35 Million CAD | 208.71% |
2020 Q4 | 2.29 Million CAD | -14.04% |
2020 Q3 | 2.66 Million CAD | -7.33% |
2019 Q2 | 1.08 Million CAD | -3.65% |
2019 FY | 1.08 Million CAD | -14.01% |
2019 Q1 | 1.12 Million CAD | -10.83% |
2019 Q4 | 1.08 Million CAD | 1.1% |
2019 Q3 | 1.07 Million CAD | -1.0% |
2018 Q4 | 1.26 Million CAD | -6.76% |
2018 Q2 | 1.57 Million CAD | -13.36% |
2018 Q3 | 1.35 Million CAD | -13.95% |
2018 Q1 | 1.82 Million CAD | 270.99% |
2018 FY | 1.26 Million CAD | 157.9% |
2017 Q2 | 138.74 Thousand CAD | -27.28% |
2017 Q4 | 490.6 Thousand CAD | 15.58% |
2017 FY | 490.6 Thousand CAD | 73.69% |
2017 Q1 | 190.78 Thousand CAD | -58.23% |
2017 Q3 | 424.45 Thousand CAD | 205.92% |
2016 Q4 | 456.71 Thousand CAD | 91.73% |
2016 Q3 | 238.21 Thousand CAD | -2.49% |
2016 Q2 | 244.3 Thousand CAD | -11.38% |
2016 Q1 | 275.67 Thousand CAD | -12.8% |
2016 FY | 282.46 Thousand CAD | 0.0% |
2015 Q4 | 316.14 Thousand CAD | 65.17% |
2015 Q3 | 191.4 Thousand CAD | -0.26% |
2015 Q2 | 191.89 Thousand CAD | 6.56% |
2015 Q1 | 180.08 Thousand CAD | 0.0% |
2014 FY | 180.08 Thousand CAD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Arch Biopartners Inc. | 1.17 Million CAD | -515.628% |
Covalon Technologies Ltd. | 24.9 Million CAD | 71.045% |
Hemostemix Inc. | 313.76 Thousand CAD | -2197.916% |
Universal Ibogaine Inc. | 6.31 Million CAD | -14.126% |
Kane Biotech Inc. | 5.68 Million CAD | -26.917% |
MedMira Inc. | 3.65 Million CAD | -97.438% |
Marvel Biosciences Corp. | 672.38 Thousand CAD | -972.304% |
NervGen Pharma Corp. | 13.23 Million CAD | 45.527% |